Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
AlloVir
company
About
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.
- 101 - 250
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $126.60M
- Industries
- Biotechnology,Clinical Trials,Pharmaceutical
- Founded date
- Jan 1, 2013
- Number Of Employee
- 101 - 250
- Operating Status
- Active
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.The company was founded in 2013 and headquartered in Houston, Texas.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$126.60M
AlloVir has raised a total of
$126.60M
in funding over 2 rounds. Their latest funding was raised on
Jul 27, 2022 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 27, 2022 | Post-IPO Equity | $126.60M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
AlloVir is funded by 1 investors.
Kite Pharma
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Kite Pharma
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
